Clinical trial · Observational
Bone Microstructure After Gastrectomy Evaluating by Using HR-pQCT
Chronological Change of Bone Microstructure After Gastrectomy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Osteoporosis after gastrectomy, which is characterized by both the loss of bone mass and the deterioration of bone architecture, is a serious complication in the long course after gastrectomy. The aim of the present study was to evaluate osteoporosis by using high-resolution peripheral quantitative computed tomography (HR-pQCT) in the long course after gastrectomy. In total gastrectomy and distal gastrectomy groups, at least 5 years should have elapsed since gastrectomy.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
| Osteoporosis | — | UNRESOLVED | — |
| Sarcopenia | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (3)
- label
- Control group
- label
- Distal Gastrectomy (DG) group
- description
- 38 patients planing distal gastrectomy due to gastric cancer
- label
- Total Gastrectomy (TG) group
- description
- 38 patients planing total gastrectomy due to gastric cancer
Primary outcomes (1)
- measure
- Comparing bone microstructure in control, DG, and TG groups
- timeFrame
- 2 years after the treatments
- description
- volumetric bone mineral density loss comparing with before the treatments
Secondary outcomes (6)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 60 Years
- Maximum age
- 79 Years
Show eligibility criteria text
Inclusion Criteria: * Planning ESD, DG, or TG due to gastric cancer * Provide signed informed consent Exclusion Criteria: * pregnancy * Current use of the following osteoporosis agents; Teriparatide, Denosumab, and bisphosphonate * Hyperthyroidism * Hyperparathyroidism * Present malignancy (except in situ carcinoma) * Any condition that required chronic (greater than three months cumulative and greater than 5 mg/day) glucocorticoid therapy * Other diseases which affect bone metabolism * Any disorder that, in the opinion of the investigator, may compromise the ability of the subject to give written informed consent and/or comply with study procedures * Received \> 3 months (or equivalent) of osteoporosis treatment * Currently enrolled in or has not yet completed at least 1 month since ending other investigational device or drug trial(s), or subject is receiving other investigational agent(s).
References
Publications (0)
Data not yet available